ArticleBMC neurology2026
Association between admission high-sensitivity cardiac troponin T levels and clinical outcomes in acute intracerebral hemorrhage: a prospective cohort study.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntracerebral hemorrhage remains one of the most devastating forms of stroke, associated with high mortality and disability. Cardiac injury following ICH, mediated through the brain-heart axis, may serve as a marker of disease severity. High-sensitivity cardiac troponin T, which rises rapidly after myocardial injury, has potential prognostic value in stroke-heart syndrome. The objective of this study was to determine whether elevated high-sensitivity cardiac troponin T levels at hospital admission is associated with early mortality, overall mortality, and poor functional outcome at 90 days in patients with acute intracerebral hemorrhage.
methodsThis is a prospective cohort study, which enrolled 256 patients with acute ICH admitted within 24 h of onset to the Stroke Center, Bach Mai Hospital, from February 2025 to June 2025. Baseline characteristics, hematoma features, comorbidities, and high-sensitivity cardiac troponin T levels were collected immediately upon admission. Clinical outcomes included early mortality (< seven days), overall mortality, and poor functional outcome (modified Rankin Scale score 4-6) were evaluated. Multivariate regression identified independent associations.
resultsElevated high-sensitivity cardiac troponin T levels was observed in 88 patients (34.4%). These patients had significantly lower Glasgow Coma Scale scores and larger hematoma volumes. Poor functional outcome occurred in 80.7% vs., 53.6% (p-value < 0.001), overall mortality in 65.9% vs., 33.9% (p-value < 0.001), and early mortality in 54.5% vs. 22.6% (p-value < 0.001) when comparing elevated and non-elevated high-sensitivity cardiac troponin T patients, respectively. After multivariable adjustment, elevated high-sensitivity cardiac troponin T (hs-cTnT) was independently associated with poor functional outcome (OR 2.41; 95% CI 1.06-5.49) and early mortality (OR 2.85; 95% CI 1.10-7.42). An association with overall mortality was also observed (OR 2.27; 95% CI 0.97-5.27), although this did not reach statistical significance. In time-to-event analyses, patients with elevated hs-cTnT experienced a significantly shorter restricted mean survival time compared with those without hs-cTnT elevation (13.9 vs. 22.4 days), corresponding to a mean survival difference of approximately 8.5 days (95% CI -11.2 to -5.8; p < 0.001).
conclusionAdmission elevated high-sensitivity cardiac troponin T was associated with adverse outcomes in acute primary intracerebral hemorrhage and showed a notable association with early mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.